Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Takeda and Sanofi Strike Diabetes Drug Co-Promotion in China

publication date: Apr 24, 2013
Takeda and Sanofi agreed to co-promote Takeda’s Alogliptin, a DPP-4 treatment for type 2 diabetes, in China. Under the terms of the agreement, Sanofi will have the exclusive right to promote the drug in certain defined territories in China. Alogliptin is currently being reviewed for marketing by the SFDA; Takeda expects an approval sometime this year. Terms of the agreement were not disclosed. More details....

Stock Symbols: (TO: 4502) (NYSE: SNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital